Bernard Ravina, MD, MSCE
Medical Director in Translational Neurology
At time of recording:
Associate Professor of Neurology
Director, Movement & Inherited Neurological Disorders Unit
Associate Director, Clinical Trials Coordination Center
University of Rochester Medical Center
Hubert H. Fernandez, MD, FAAN
Head, Movement Disorders Program
Center for Neurological Restoration
At time of recording:
Vice-Chair for Academic Affairs
Director, Clinical Trials Center for Neurological Disorders
Department of Neurology
University of Florida
Physicians: 1 Credit Hour
Nurses: 1 Contact Hour Medium
Parkinson's disease (PD) is a progressive neurodegenerative movement disorder that is estimated to affect approximately 1 million adults in the United States. PD affects both motor and cognitive function. There are no strict treatment guidelines; the goal of therapy is to provide the best possible level of functioning and quality of life. A number of knowledge gaps have been identified regarding the clinical management of PD, including timing of treatment initiation, the impact of unique patient factors on treatment plans, the differences between MAO-B inhibitors and other classes of pharmaceutical agents that contribute to variable rates of efficacy and safety, and knowledge of ongoing disease modification trials.
Findings from recent clinical research can provide clinicians with the tools to develop effective treatment regimens based on individual patient characteristics. Continuing medical education programs that highlight optimal methods of diagnosis and treatment of PD are likely to contribute to improved symptom progression and quality of life in patients with PD.
METHOD OF PARTICIPATION: Participants will listen to a pre-recorded audio presentation via telephone while viewing the slides. Question-and-answers recorded with the faculty during the previous live audioconferences will follow the presentation. Program Developer/Facilitator
Jointly Provided by AKH Inc. and MCM Education Target Audience
This program has been developed for general neurologists, gerontologists, advanced practice nurses, nurse practitioners, and other healthcare providers involved in the care of patients with Parkinson’s disease.
Upon completion of this educational activity, the participant should be able to:
Identify early features of Parkinson's disease (PD) to expedite diagnosis of PD
Develop customized treatment plans for PD patients based on unique phases and clinical manifestations of PD
Discuss the clinical differences between MAO-B inhibitors and other classes of pharmaceutical agents that may impact therapeutic decisions for individual patients
Review ongoing trials for PD and their potential to improve motor function, mental health, and cognition in patients with PD
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Dr. Ravina discloses that he has received research support from EnVivo Pharmaceuticals, Medivation, Boehringer Ingelheim Pharmaceuticals, and Teva Pharmaceuticals. He has received support for consulting from Acadia Pharmaceuticals, Novartis Pharmaceuticals, Vernalis plc, Link Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Teva Pharmaceuticals, Upsher-smith, and Ipsen Group.
Dr. Fernandez discloses that he has received research support from AstraZeneca, Forest Laboratories, Novartis Pharmaceuticals, Solvay, and Teva Pharmaceuticals.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
Physician Continuing Medical Education: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurse Continuing Education: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
AKH Inc. designates this educational activity for 1 contact hour (0.1 CEU). Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA.
Participants must view/listen to the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing education credit. Credit will be awarded for a score of 70% or better, and a statement may be printed immediately after passing the post-test online.
Commercial Support Statements
Supported by an independent educational grant from Teva Neuroscience.
Minimum System Requirements:
• Pentium III, 600 MHz or Equivalent Processor
• 512 MB of RAM
• Windows XP, Vista, or 7
• Mac OS X
• 800x600 Monitor Resolution
• 16-bit Color
• 16 bit Sound Card with Speakers
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 60 minutes to complete.
After the program has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen. A credit statement/certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.